Key Details
Price
$9.77Annual Revenue
$174.53 MAnnual EPS
$0.07Annual ROE
6.66%Beta
0.70Events Calendar
Next earnings date:
Mar 12, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Mar 12, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
I maintain a buy rating for ENFN, anticipating revenue growth to exceed 20% due to improving macro conditions and solid execution. The macro environment has shown signs of turnaround, with rate cuts and reduced election uncertainty, boosting demand sentiment. ENFN's strong execution is evident in stable front book revenue growth, customer additions, and successful upmarket penetration.
Enfusion, Inc. (NYSE:ENFN ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - Chief Executive Officer Bradley Herring - Chief Financial Officer Neal Pawar - Chief Operating Officer Conference Call Participants Michael Infante - Morgan Stanley Dylan Becker - William Blair Parker Lane - Stifel Kevin McVeigh - UBS Elise Kenner - JP Morgan Gabriela Borges - Goldman Sachs Koji Ikeda - Bank of America Crispin Love - Piper Sandler Operator Good morning, ladies and gentlemen. Thank you for standing by.
Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
FAQ
- What is the primary business of Enfusion?
- What is the ticker symbol for Enfusion?
- Does Enfusion pay dividends?
- What sector is Enfusion in?
- What industry is Enfusion in?
- What country is Enfusion based in?
- When did Enfusion go public?
- Is Enfusion in the S&P 500?
- Is Enfusion in the NASDAQ 100?
- Is Enfusion in the Dow Jones?
- When was Enfusion's last earnings report?
- When does Enfusion report earnings?
- Should I buy Enfusion stock now?